1. Home
  2. LPTX vs MHLD Comparison

LPTX vs MHLD Comparison

Compare LPTX & MHLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPTX
  • MHLD
  • Stock Information
  • Founded
  • LPTX 2011
  • MHLD 2007
  • Country
  • LPTX United States
  • MHLD Bermuda
  • Employees
  • LPTX N/A
  • MHLD N/A
  • Industry
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • MHLD Property-Casualty Insurers
  • Sector
  • LPTX Health Care
  • MHLD Finance
  • Exchange
  • LPTX Nasdaq
  • MHLD Nasdaq
  • Market Cap
  • LPTX 119.6M
  • MHLD 96.4M
  • IPO Year
  • LPTX N/A
  • MHLD 2008
  • Fundamental
  • Price
  • LPTX $0.48
  • MHLD $0.87
  • Analyst Decision
  • LPTX Buy
  • MHLD
  • Analyst Count
  • LPTX 3
  • MHLD 0
  • Target Price
  • LPTX $8.50
  • MHLD N/A
  • AVG Volume (30 Days)
  • LPTX 1.5M
  • MHLD 129.2K
  • Earning Date
  • LPTX 03-17-2025
  • MHLD 03-11-2025
  • Dividend Yield
  • LPTX N/A
  • MHLD N/A
  • EPS Growth
  • LPTX N/A
  • MHLD N/A
  • EPS
  • LPTX N/A
  • MHLD N/A
  • Revenue
  • LPTX N/A
  • MHLD $89,074,000.00
  • Revenue This Year
  • LPTX N/A
  • MHLD N/A
  • Revenue Next Year
  • LPTX N/A
  • MHLD N/A
  • P/E Ratio
  • LPTX N/A
  • MHLD N/A
  • Revenue Growth
  • LPTX N/A
  • MHLD 20.80
  • 52 Week Low
  • LPTX $0.47
  • MHLD $0.83
  • 52 Week High
  • LPTX $4.79
  • MHLD $2.27
  • Technical
  • Relative Strength Index (RSI)
  • LPTX 19.00
  • MHLD 37.29
  • Support Level
  • LPTX $0.47
  • MHLD $0.85
  • Resistance Level
  • LPTX $0.53
  • MHLD $1.29
  • Average True Range (ATR)
  • LPTX 0.04
  • MHLD 0.08
  • MACD
  • LPTX 0.07
  • MHLD 0.01
  • Stochastic Oscillator
  • LPTX 7.42
  • MHLD 17.43

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

About MHLD Maiden Holdings Ltd.

Maiden Holdings Ltd provides reinsurance products and services to regional and specialty property and casualty insurers. The company operates in two segments: AmTrust Reinsurance and Diversified Reinsurance. The AmTrust Reinsurance segment provides products that cover workers' compensation, commercial package, commercial auto, and extended warranty. The Diversified Reinsurance segment provides small and midsize regional and specialty insurers with reinsurance capital products. Its revenues also include fee income earned from both its GLS business and IIS business as well as income generated from its investment portfolio.

Share on Social Networks: